Northwest Biotherapeutics Reveals Revised Survival Findings for DCVax®-L in Glioblastoma Phase III Study

In a groundbreaking presentation at the 2026 Annual Meeting of the British Neuro-Oncology Society, Northwest Biotherapeutics (OTCQB:NWBO) disclosed updated survival results from its pivotal Phase III trial of DCVax®-L, a personalized immune therapy designed for glioblastoma, an aggressive form of brain cancer. Chief Technical Officer Dr. Marnix Bosch revealed that the initial assessments of survival extensions may have been significantly underestimated.

Traditionally, the survival data reported was based on cohort-level information, limiting the accuracy for comparisons between patients treated with DCVax-L and control groups. Recent advancements in data accessibility allowed the Company access to individual patient-level data (IPD) from major randomized controlled trials concerning newly diagnosed glioblastoma. The transition from cohort-level data to IPD marked a turning point as it offered more precise patient matching, ultimately yielding a more accurate insight into the treatment effects of DCVax-L.

In the refined analyses, two robust statistical methodologies—propensity score matching (PSM) and inverse probability weighting (IPW)—were employed by independent statisticians. These analyses produced remarkable findings: the PSM analysis of two large randomized controlled trials identified a median survival benefit for those treated with DCVax-L ranging from 4.9 to 6.3 months. Another PSM examination of a third randomized trial indicated a 3.4 to 3.7 month survival advantage. Furthermore, the Hazard Ratios observed, varying from 0.69 to 0.77, illustrated a significant implication of treatment efficacy, with p-values from 0.004 to 0.027, all substantially surpassing results from the original cohort-level data which noted only a 2.8-month advantage.

Moreover, the IPW analysis reaffirmed similar findings, indicating a median survival benefit associated with DCVax-L between 3.4 to 4.3 months. This consistency across the analyses lends further credibility to the assertion that prior estimates underestimated the true efficacy of the treatment.

To ensure the robustness of the findings and to account for potential unrecognized biases, the statisticians conducted sensitivity analyses. By utilizing E Values and Rosenbaum's Gamma, they verified that the substantial treatment effects attributed to DCVax-L were not influenced by hidden imbalances between the treatment and control populations.

Dr. Bosch remarked on the significance of these findings, stating, "The new PSM and IPW analyses, along with the results from sensitivity checks, provide compelling evidence supporting the survival benefit that DCVax-L treatment offers. All analyses from differing methodologies converge towards a consistent estimation, indicating that the previous survival benefit reported was likely miscalculated and undervalued."

As a pioneering biotechnology firm, Northwest Biotherapeutics is committed to advancing its DCVax® dendritic cell-based vaccine platform designed to combat solid tumors more effectively than conventional cancer treatments, while minimizing harmful side effects commonly associated with chemical therapies. The company has made substantial progress, completing a 331-patient Phase III trial for DCVax-L targeting glioblastoma, with results showcased at notable scientific meetings and published in reputable journals like JAMA Oncology.

The company has also applied for a Marketing Authorization Application (MAA) in the UK, which is presently under different stages of review. Additionally, the organization aims to extend its efforts in developing DCVax®-Direct, aimed at inoperable solid tumors, having successfully completed a Phase I trial and planning further Phase II trials in the upcoming year.

Northwest Biotherapeutics continues to stand at the forefront of personalized cancer treatment innovation, tirelessly working to improve survival outcomes while ensuring safety and efficacy in their clinical offerings.